89BIO, INC. (ETNB): Price and Financial Metrics


89BIO, INC. (ETNB): $2.99

0.19 (+6.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ETNB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ETNB Stock Price Chart Interactive Chart >

Price chart for ETNB

ETNB Price/Volume Stats

Current price $2.99 52-week high $22.31
Prev. close $2.80 52-week low $2.00
Day low $2.80 Volume 124,000
Day high $3.01 Avg. volume 201,791
50-day MA $3.04 Dividend yield N/A
200-day MA $10.91 Market Cap 60.85M

89BIO, INC. (ETNB) Company Bio


89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.


ETNB Latest News Stream


Event/Time News Detail
Loading, please wait...

ETNB Latest Social Stream


Loading social stream, please wait...

View Full ETNB Social Stream

Latest ETNB News From Around the Web

Below are the latest news stories about 89bio Inc that investors may wish to consider to help them evaluate ETNB as an investment opportunity.

89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors

SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors. Dr. Atkinson currently serves as Senior Vice President, Head of Commercial Manufacturing and Supply Chain of Vertex Pharmaceuticals. “As a seasoned biopharmaceu

Yahoo | February 24, 2022

89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00 PM ET.

GlobeNewswire | February 9, 2022

CEO & Director Rohan Palekar Just Bought 90% More Shares In 89bio, Inc. (NASDAQ:ETNB)

Whilst it may not be a huge deal, we thought it was good to see that the 89bio, Inc. ( NASDAQ:ETNB ) CEO & Director...

Yahoo | February 3, 2022

89bio's stock gains 4% on new data for experimental NASH treatment

Shares of 89bio Inc. were up 4.2% in premarket trading on Tuesday, the day after the company shared encouraging, early-stage data from a clinical trial assessing an experimental therapy called pegozafermin as a treatment for non-alcoholic steatohepatitis. "We continue to view the FGF21 analogs as one of the most compelling classes of drugs being developed in NASH," SVB Leerink analyst Thomas Smith told investors on Tuesday. Brian Abrahams, an analyst at RBC Capital Markets, wrote Monday that the

Yahoo | January 25, 2022

89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%) and fibrosis improvement (26%)Robust changes on multiple non-invasive liver tests, markers of cardiovascular health and glycemic control support pegozafermin’s potential as a compelling treatment option for NASH Phase 2b ENLIVEN trial ongoing in NASH patients with results expected in first half 2023Conference

Yahoo | January 24, 2022

Read More 'ETNB' Stories Here

ETNB Price Returns

1-mo 26.69%
3-mo -36.65%
6-mo -77.31%
1-year -84.18%
3-year N/A
5-year N/A
YTD -77.12%
2021 -46.37%
2020 -7.30%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4379 seconds.